REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (RGNX) will participate in two investor conferences: the Barclays Global Healthcare Conference on March 17, 2022, at 11:15 a.m. ET in Miami, FL, and the Morgan Stanley Healthcare Corporate Access Day on March 29, 2022, in Boston, MA.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO Inc. (RGNX) will participate in two investor conferences: the Barclays Global Healthcare Conference on March 17, 2022, at 11:15 a.m. ET in Miami, FL, and the Morgan Stanley Healthcare Corporate Access Day on March 29, 2022, in Boston, MA. A live webcast of the Barclays presentation will be available on the company's website, with an archived replay accessible for 30 days. REGENXBIO is a clinical-stage biotechnology firm focused on gene therapy, utilizing its NAV Technology Platform for a variety of therapeutic developments.
Details
News Market Reaction – RGNX
The recorded move for RGNX in the trading session of this news was -0.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., March 9, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
Barclays Global Healthcare Conference
Date: Thursday, March 17, 2022
Location: Loews Miami Beach Hotel, Miami, FL
Presentation: Thursday, March 17, 2022 at 11:15 a.m. ET
Morgan Stanley Healthcare Corporate Access Day
Date: Tuesday, March 29, 2022
Location: Boston Harbor Hotel, Boston, MA
A webcast of the Barclays presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301498746.html
SOURCE REGENXBIO Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.